The immunosuppressive tumor microenvironment has caused great obstacles to
tumor immunotherapy, especially where less
tumor-associated
antigens are released from
tumor sites. Herein, a Ag2S QD/DOX/
Bestatin@PC10ARGD genetically engineered
polypeptide hydrogel PC10ARGD as a sustained-release material was developed for mammary
carcinoma treatment. A near-infrared
silver sulfide (Ag2S) QD as a
photosensitizer was encapsulated into the hydrophobic cavity formed by the self-assembly of the
polypeptide nanogel (PC10ARGD) for
photothermal therapy. The water-soluble drug DOX and
Bestatin were integrated into the PC10ARGD
hydrogel. The photothermal effect could trigger the sustained release of the DOX, which could be applied to initiate in situ vaccination.
Bestatin as an immune-adjuvant drug could amplify the body's immune function. The results of in vivo
therapy tests exhibited that the Ag2S QD/DOX/
Bestatin@PC10ARGD
hydrogel with
laser irradiation could activate anti-
tumor immune effects that inhibit the growth of primary
tumors and distal lung metastatic nodules. Meanwhile, a safer lower-temperature with multiple
laser irradiation treatment strategy exhibited more effective
tumor-killing performance (84.4%
tumor inhibition rate) and promoted the penetration of immune cells into the
tumor tissue. The CD8+ and CD4+ cytotoxic T cells ratio was increased by 5.3 and 10 times, respectively, thus exhibiting a good prognostic signal. The multifunctional
polypeptide hydrogel as a green manufacturing and engineering material is promising to serve as a
cancer vaccine for anticancer applications.